FDA Approves First Dual-AAV Gene Therapy for Genetic Hearing Loss Under Priority Voucher Program
By
Office of the Commissioner
Not artisan, but a perfectly fine bagel. Hits the spot.
Summary
The FDA has approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy for treating genetic hearing loss. This landmark approval was facilitated under a National Priority Voucher Program, marking a significant breakthrough in gene therapy and hearing loss treatment. The therapy targets specific genetic mutations that cause hearing loss, offering a potential cure rather than just symptom management.
Key quotes
· 3 pulledThe U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy.
This approval represents a major milestone in the treatment of genetic hearing loss, offering new hope to patients with this condition.
The National Priority Voucher Program has accelerated the development and review of this groundbreaking therapy.
You might also wanna read
Single Infusion of Gene-Editing Therapy VERVE-102 Shows Promise for Inherited High Cholesterol
An experimental gene-editing therapy called VERVE-102, developed by Verve Therapeutics (a subsidiary of Eli Lilly), shows promise in treatin
discovermagazine.com·2d ago
Eli Lilly's experimental gene-editing therapy VERVE-102 shows promise as one-time treatment for high cholesterol
Eli Lilly is testing VERVE-102, an experimental gene-editing therapy for high cholesterol that could be administered as a one-time infusion
abcnews.com·3d ago
First In-Vivo Gene-Editing Therapy Successfully Saves Newborn's Life in 2025
In 2025, doctors and scientists in the U.S. successfully performed the world's first custom gene-editing therapy inside a living person—a ne
popularmechanics.com·5mo ago
Google's Debug program seeks EPA approval to release 64 million modified mosquitoes in California and Florida
Google's Debug program plans to release up to 64 million genetically modified "good" mosquitoes in California and Florida over two years to
bit.ly·40m ago
Researchers develop phage-based preventive treatment for newborn meningitis caused by E. coli K1
Researchers from the Biozentrum, University of Basel, and ETH Zurich have developed a novel preventive treatment for newborn meningitis caus
biozentrum.unibas.ch·1h ago
Daily pill daraxonrasib doubles survival for metastatic pancreatic cancer patients with KRAS mutation
A new daily pill called daraxonrasib has been shown to double survival time for metastatic pancreatic cancer patients with a KRAS mutation.
bbc.co.uk·4h ago